IOncology

Microsatellite stable (MSS) and mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC) has shown minimal response to immune checkpoint inhibitors as monotherapy, making combination immunotherapy a key strategy to address this clinical challenge. At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), a multicenter phase II study led by Dr. Rongbo Lin from Fujian Cancer Hospital was selected for the poster abstract session (Abstract #198). This study evaluates the preliminary efficacy and safety of FOLFOXIRI combined with bevacizumab and cadonilimab in pMMR/MSS mCRC patients.  During the conference, a reporter from Oncology Frontier conducted an in-depth interview with Dr. Rongbo Lin to discuss the study findings.

From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) was held in San Francisco, showcasing significant advancements in gastrointestinal cancer treatment. The Peking University Cancer Hospital presented a series of cutting-edge findings, contributing to global progress in digestive tract oncology. On the first day of the conference, Dr. Zhi Peng from Peking University Cancer Hospital delivered an oral presentation on the latest findings from a Phase III clinical study evaluating the domestically developed PD-L1/TGF-βRII bispecific fusion protein SHR-1701 in first-line treatment for HER2-negative gastric and gastroesophageal junction adenocarcinoma (G/GEJA). Building upon the efficacy improvements previously reported at the European Society for Medical Oncology (ESMO) Congress, the latest data presented at ASCO GI suggests that SHR-1701 combined with chemotherapy may mitigate chemotherapy-induced bone marrow suppression, offering a more effective and safer treatment option for G/GEJA.

Dr. Charles Geyer, Jr.. presented findings from the NSABP B-59/GBG-96-GeparDouze phase III trial, evaluating the addition of atezolizumab to neoadjuvant chemotherapy, followed by adjuvant atezolizumab, in stage II-III triple-negative breast cancer (TNBC).

At ASCO GI 2025, Anna Dorothea Wagner and colleagues presented the EORTC-1203 "INNOVATION" trial, investigating trastuzumab (T) ± pertuzumab (P) with perioperative chemotherapy (CT) in HER2+ gastric and esophagogastric junction…

At ASCO GI 2025, Thierry André and colleagues presented CheckMate 8HW results, showing nivolumab (NIVO) + ipilimumab (IPI) outperforms NIVO alone in MSI-H/dMMR metastatic colorectal cancer (mCRC).Key findings:✅ PFS significantly…

A new phase 3 study, led by Scott Kopetz and an international team, provides strong evidence supporting encorafenib + cetuximab (EC) with mFOLFOX6 as a first-line treatment for BRAF V600E-mutant…

A recent study led by Anna Martling, the ALASCCA trial, provides new evidence that low-dose aspirin (160 mg daily) can reduce recurrence risk in colorectal cancer (CRC) patients with PI3K…

Prostate cancer is one of the most common malignancies affecting the male genitourinary system, and in China, a significant proportion of newly diagnosed patients present with advanced disease. Since late-stage prostate cancer is symptomatic and not curable, alleviating symptoms, delaying disease progression, and improving quality of life have always been priorities for both patients and physicians in China. In 2024, several groundbreaking studies on advanced prostate cancer, including metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC), were published in leading medical journals and presented at international conferences, reshaping treatment paradigms. With a retrospective look at the past year, Oncology Frontier invited Dr. Dingwei Ye from Fudan University Shanghai Cancer Center to share insights on these advancements.

Introduction: Gastrointestinal (GI) cancers remain a significant challenge in oncology, with conventional therapies often yielding limited success in advanced cases. Recent advances in cellular therapies, particularly chimeric antigen receptor T-cell…